Improved sensitivity of early diagnostic screening tools has highlighted grave concerns regarding the surge in gonorrhea incidences. As per a survey conducted by the Centers for Disease Control and Prevention, 555,608 cases of gonorrhea were reported in 2017, in the U.S., demonstrating an increase of 18.6% from 2009. These figures have hard-pressed the governments of numerous countries to take preventive and curative measures for relegating the prevalence of gonorrhea.
According to the gonorrhea therapeutics market research report published by Transparency Market Research (TMR), women are more susceptible to this disease than men, and the number of women availing therapeutics is on an exponential increase, thereby making women the key demographic of the market. The scramble of market players towards addressing the issue at the grass-root level has engendered several vaccines, including 4CMenB and rLP2086, which harbingers steady growth prospects for the landscape. However, literatures claiming the progressive resistance of gonorrhea to therapeutics could surface uncertainties regarding market advancement.
To know the scope of our report Get a Sample on Gonorrhea Therapeutics Market
The connection of gonorrhea with infertility has accelerated the pace of research & development activities among market players to introduce effective therapeutics to combat this public health threat. A research team at the Louisiana State University Health Sciences discovered a novel antibiotic - zoliflodacin - to inhibit bacteria’s DNA synthesis with a differentiated approach than current antibiotics, which was well-received by the FDA, and the same has been marketed as an oral treatment for gonorrhea. Besides oral drugs, medical personnel recommend dual therapy over monotherapy, given the growing resistance of Neisseria Gonorrhoeae to antibiotics.
A majority of women with gonorrhea show subtle signs of ongoing damage to the uterine tract, which, if left untreated, could cause involuntary infertility, ectopic pregnancy, or even chronic pelvic pain. As a result, this TMR study identifies that, the number of women availing gonorrhea therapeutics is projected to rise at a CAGR of ~6% during 2019-2027, with uncomplicated gonococcal infection being the leading cause.
Get a glimpse of the in-depth analysis through our Report Brochure
The sales of gonorrhea therapeutics are projected to witness significant uptake from hospital pharmacies, as hospitals remain preferred care centers for patients diagnosed with gonorrhea. According to TMR’s estimates, hospital pharmacies will account for a value tantamount to ~US$ 548 Mn in 2019, out of which, ~37% of sales will come from hospital pharmacies based in North America alone.
Propitious environment for the growth of the healthcare sector in North America that is attributable to the intervention of the government in creating awareness regarding the prevalence of diseases, and hefty financial allocations for R&D activities are also likely to reflect on the advancement of the gonorrhea therapeutics market. Currently, North America monopolizes the gonorrhea therapeutics market; however, the Asia Pacific market holds profitable prospects on account of the growing sprawl of bacterial infections. On top of it, improvements in healthcare infrastructure coupled with financial lucidity of individuals has encouraged a large base to opt for effective gonorrhea therapeutics.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Authors of the report opine that, the gonorrhea therapeutics market will rise from ~US$ 1.4 Bn in 2019 to ~US$ 2 Bn in 2027, representing a CAGR of ~5% during the forecast period, with the shifting paradigm from a preventive to curative healthcare approach. A heated competitive landscape in the global pharmaceutical vicinity is encouraging market players to penetrate into new markets to channelize the supply of therapeutics and consolidate their market position.
However, the same is not achieved only by forward integration but also by inorganic practices such as acquisitions, mergers, and collaborations, in order to establish distribution partnerships with regional and local players. For instance, AstraZeneca announced the acquisition of Takeda Pharmaceutical Company Limited to expand in regions with high growth potential. To add to that, market players can prioritize investments towards the development of vaccines to infiltrate into the market with a curative approach
Gonorrhea Therapeutics Market: Overview
Global Gonorrhea Therapeutics Market: Drivers & Restraints
Global Gonorrhea Therapeutics Market: Segment Analysis
Global Gonorrhea Therapeutics Market: Regional Segmentation
Global Gonorrhea Therapeutics Market: Major Players
Gonorrhea Therapeutics Market - Segmentation
In order to present an incisive view of the gonorrhea therapeutics market, analysts and researchers of the report have segregated the gonorrhea therapeutics market based on the gonococcal infection, treatment, route of administration, gender, distribution channel, and region. This comprehensive business study also analyzes the incremental opportunity present in the gonorrhea therapeutics market during the forecast period. The key segments of the gonorrhea therapeutics market are as mentioned below:
|
Gonococcal Infection |
|
|
Treatment |
|
|
Route of Administration |
|
|
Gender |
|
|
Distribution Channel |
|
|
Region |
|
Gonorrhea therapeutics market to reach a valuation of ~US$ 2 Bn by 2027
Gonorrhea therapeutics market to expand at a CAGR of ~5.3% from 2019 to 2027
Gonorrhea therapeutics market is driven by rising prevalence of gonorrhea and use of new diagnostic tests
North America accounted for a major share of the global gonorrhea therapeutics market
Key players in the global gonorrhea therapeutics market include GlaxoSmithKline plc. Merck & Co., Inc., Pfizer Inc, AstraZeneca, Hologic, Inc., Danaher
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gonorrhea Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Gonococcal Infection Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gonorrhea Therapeutics Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Regulatory Scenario by Region/globally
5.2. Reimbursement Scenario by Region/globally
6. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Gonococcal Infection Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027
6.3.1. Uncomplicated Gonococcal Infection
6.3.2. Gonococcal Arthritis
6.3.3. Gonococcal Meningitis and Endocarditis
6.4. Global Gonorrhea Therapeutics Market Attractiveness, by Gonococcal Infection Type
7. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Treatment
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027
7.3.1. Monotherapy
7.3.2. Dual Therapy
7.4. Global Gonorrhea Therapeutics Market Attractiveness, by Treatment
8. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027
8.3.1. Oral
8.3.2. Injectable
8.4. Global Gonorrhea Therapeutics Market Attractiveness, by Route of Administration
9. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Gender
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Global Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027
9.3.1. Women
9.3.2. Men
9.4. Global Gonorrhea Therapeutics Market Attractiveness, by Gender
10. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Global Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.3.4. Others
10.4. Global Gonorrhea Therapeutics Market Attractiveness, by Distribution Channel
11. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Global Gonorrhea Therapeutics Market Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Global Gonorrhea Therapeutics Market Attractiveness, by Region
12. North America Gonorrhea Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. North America Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027
12.2.1. Uncomplicated Gonococcal Infection
12.2.2. Gonococcal Arthritis
12.2.3. Gonococcal Meningitis and Endocarditis
12.3. North America Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027
12.3.1. Monotherapy
12.3.2. Dual Therapy
12.4. North America Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027
12.4.1. Oral
12.4.2. Injectable
12.5. North America Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027
12.5.1. Women
12.5.2. Men
12.6. North America Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.6.4. Others
12.7. North America Gonorrhea Therapeutics Market Forecast, by Country, 2017–2027
12.7.1. U.S.
12.7.2. Canada
12.8. North America Gonorrhea Therapeutics Market Attractiveness Analysis
12.8.1. By Gonococcal Infection Type
12.8.2. By Treatment
12.8.3. By Route of Administration
12.8.4. By Gender
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Gonorrhea Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Europe Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027
13.2.1. Uncomplicated Gonococcal Infection
13.2.2. Gonococcal Arthritis
13.2.3. Gonococcal Meningitis and Endocarditis
13.3. Europe Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027
13.3.1. Monotherapy
13.3.2. Dual Therapy
13.4. Europe Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027
13.4.1. Oral
13.4.2. Injectable
13.5. Europe Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027
13.5.1. Women
13.5.2. Men
13.6. Europe Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.6.4. Others
13.7. Europe Gonorrhea Therapeutics Market Forecast, by Country/Sub-region, 2017–2027
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Europe Gonorrhea Therapeutics Market Attractiveness Analysis
13.8.1. By Gonococcal Infection Type
13.8.2. By Treatment
13.8.3. By Route of Administration
13.8.4. By Gender
13.8.5. By Distribution Channel
13.8.6. By Country
14. Asia Pacific Gonorrhea Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027
14.2.1. Uncomplicated Gonococcal Infection
14.2.2. Gonococcal Arthritis
14.2.3. Gonococcal Meningitis and Endocarditis
14.3. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027
14.3.1. Monotherapy
14.3.2. Dual Therapy
14.4. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027
14.4.1. Oral
14.4.2. Injectable
14.5. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027
14.5.1. Women
14.5.2. Men
14.6. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.6.4. Others
14.7. Asia Pacific Gonorrhea Therapeutics Market Forecast, by Country/Sub-region, 2017–2027
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis
14.8.1. By Gonococcal Infection Type
14.8.2. By Treatment
14.8.3. By Route of Administration
14.8.4. By Gender
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Gonorrhea Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Latin America Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027
15.2.1. Uncomplicated Gonococcal Infection
15.2.2. Gonococcal Arthritis
15.2.3. Gonococcal Meningitis and Endocarditis
15.3. Latin America Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027
15.3.1. Monotherapy
15.3.2. Dual Therapy
15.4. Latin America Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027
15.4.1. Oral
15.4.2. Injectable
15.5. Latin America Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027
15.5.1. Women
15.5.2. Men
15.6. Latin America Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.6.4. Others
15.7. Latin America Gonorrhea Therapeutics Market Forecast, by Country/Sub-region, 2017–2027
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Latin America Gonorrhea Therapeutics Market Attractiveness Analysis
15.8.1. By Gonococcal Infection Type
15.8.2. By Treatment
15.8.3. By Route of Administration
15.8.4. By Gender
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Gonorrhea Therapeutics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2027
16.2.1. Uncomplicated Gonococcal Infection
16.2.2. Gonococcal Arthritis
16.2.3. Gonococcal Meningitis and Endocarditis
16.3. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2027
16.3.1. . Monotherapy
16.3.2. Dual Therapy
16.4. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2027
16.4.1. Oral
16.4.2. Injectable
16.5. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2027
16.5.1. Women
16.5.2. Men
16.6. Middle East & Africa Gonorrhea Therapeutics Market Forecast, by Distribution Channel, 2017–2027
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.6.4. Others
16.7. Middle East & Africa Gonorrhea Therapeutics Market Forecast by Country/Sub-region, 2017–2027
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Israel
16.7.4. Rest of Middle East & Africa
16.8. Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis
16.8.1. By Gonococcal Infection Type
16.8.2. By Treatment
16.8.3. By Route of Administration
16.8.4. By Gender
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (by Tier and Size of companies)
17.2. Market Share Analysis by Company (2018)
17.3. Company Profiles
17.3.1. GlaxoSmithKline plc.
17.3.1.1 Company Overview (Headquarters, Business Segments, Employee Strength)
17.3.1.2 Financial Overview
17.3.1.3 SWOT Analysis
17.3.1.4 Strategic Overview
17.3.2. Merck & Co., Inc.
17.3.2.1 Company Overview (Headquarters, Business Segments, Employee Strength)
17.3.2.2 Financial Overview
17.3.2.3 SWOT Analysis
17.3.2.4 Strategic Overview
17.3.3. Pfizer Inc.
17.3.3.1 Company Overview (Headquarters, Business Segments, Employee Strength)
17.3.3.2 Financial Overview
17.3.3.3 SWOT Analysis
17.3.3.4 Strategic Overview
17.3.4. AstraZeneca
17.3.4.1 Company Overview (Headquarters, Business Segments, Employee Strength)
17.3.4.2 Financial Overview
17.3.4.3 SWOT Analysis
17.3.4.4 Strategic Overview
17.3.5. Hologic, Inc.
17.3.5.1 Company Overview (Headquarters, Business Segments, Employee Strength)
17.3.5.2 Financial Overview
17.3.5.3 SWOT Analysis
17.3.5.4 Strategic Overview
17.3.6. Danaher
17.3.6.1 Company Overview (Headquarters, Business Segments, Employee Strength)
17.3.6.2 Financial Overview
17.3.6.3 SWOT Analysis
17.3.6.4 Strategic Overview
17.3.7. Abbott
17.3.7.1 Company Overview (Headquarters, Business Segments, Employee Strength)
17.3.7.2 Financial Overview
17.3.7.3 SWOT Analysis
17.3.7.4 Strategic Overview
17.3.8. Becton Dickinson and Company
17.3.8.1 Company Overview (Headquarters, Business Segments, Employee Strength)
17.3.8.2 Financial Overview
17.3.8.3 SWOT Analysis
17.3.8.4 Strategic Overview
17.3.9. F. Hoffmann-La Roche Ltd
17.3.9.1 Company Overview (Headquarters, Business Segments, Employee Strength)
17.3.9.2 Financial Overview
17.3.9.3 SWOT Analysis
17.3.9.4 Strategic Overview
17.3.10. Other Prominent Key Players
*Note: Financial details for companies that do not report this information in public domain might not be captured.
List of Tables
Table 1: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 2: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 3: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 4: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 5: Global Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 6: North America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 7: North America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 8: North America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 9: North America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 10: North America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 11: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 12: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 13: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 14: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 15: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 16: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 17: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 18: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 19: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 20: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 21: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 22: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 23: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 24: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 25: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 26: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gonococcal Infection, 2017–2027
Table 27: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
Table 28: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 29: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 30: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
List of Figures
Figure 1: Market Size, by Test Type (US$ Mn), 2018
Figure 2: Market Share, Top Trends, by Product Type
Figure 3: Global Gonorrhea Therapeutics Market Size (US$ Mn) and Forecast, 2018–2027
Figure 4: Global Gonorrhea Therapeutics Market Value Share, by Gonococcal Infection (2018)
Figure 5: Global Gonorrhea Therapeutics Market Value Share, by Treatment (2018)
Figure 6: Global Gonorrhea Therapeutics Market Value Share, by Route of Administration (2018)
Figure 7: Global Gonorrhea Therapeutics Market Value Share, by Gender (2018)
Figure 8: Global Gonorrhea Therapeutics Market Value Share, by Distribution Channel (2018)
Figure 9: Global Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027
Figure 10: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Uncomplicated Gonococcal Infection, 2017–2027
Figure 11: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Gonococcal Arthritis, 2017–2027
Figure 12: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Gonococcal Meningitis and Endocarditis, 2017–2027
Figure 13: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2019–2027
Figure 14: Global Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 15: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Monotherapy, 2017–2027
Figure 16: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Dual Therapy, 2017–2027
Figure 17: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2019–2027
Figure 18: Global Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 19: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017–2027
Figure 20: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Injectable 2017–2027
Figure 21: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 22: Global Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027
Figure 23: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Women, 2017–2027
Figure 24: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Men 2017–2027
Figure 25: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2019–2027
Figure 26: Global Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 27: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027
Figure 28: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027
Figure 29: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027
Figure 30: Global Gonorrhea Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 31: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 32: Global Gonorrhea Therapeutics Market Value Share Analysis, by Region, 2018 and 2027
Figure 33: Global Gonorrhea Therapeutics Market Attractiveness Analysis, by Region, 2019–2027
Figure 34: North America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027
Figure 35: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027
Figure 36: North America Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027
Figure 37: North America Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 38: North America Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 39: North America Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027
Figure 40: North America Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 41: North America Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027
Figure 42: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027
Figure 43: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027
Figure 44: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027
Figure 45: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027
Figure 46: North America Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027
Figure 47: Europe Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027
Figure 48: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027
Figure 49: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027
Figure 50: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 51: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 52: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027
Figure 53: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 54: Europe Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027
Figure 55: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027
Figure 56: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027
Figure 57: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027
Figure 58: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027
Figure 59: Europe Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027
Figure 60: Asia Pacific Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027
Figure 61: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027
Figure 62: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027
Figure 63: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 64: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 65: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027
Figure 66: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 67: Asia Pacific Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027
Figure 68: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027
Figure 69: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027
Figure 70: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027
Figure 71: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027
Figure 72: Asia Pacific Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027
Figure 73: Latin America Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027
Figure 74: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2019–2027
Figure 75: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027
Figure 76: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 77: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 78: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027
Figure 79: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 80: Latin America Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027
Figure 81: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027
Figure 82: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027
Figure 83: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027
Figure 84: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027
Figure 85: Latin America Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027
Figure 86: Middle East & Africa Gonorrhea Therapeutics Market Value (US$ Mn) Forecast, 2017–2027
Figure 87: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Country, 2018–2027
Figure 88: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Gonococcal Infection, 2018 and 2027
Figure 89: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 90: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 91: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Gender, 2018 and 2027
Figure 92: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 93: Middle East & Africa Gonorrhea Therapeutics Market Value Share Analysis, by Country, 2018 and 2027
Figure 94: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Gonococcal Infection, 2018?2027
Figure 95: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Treatment, 2018?2027
Figure 96: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Route of Administration, 2018?2027
Figure 97: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Gender, 2018?2027
Figure 98: Middle East & Africa Gonorrhea Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2018?2027
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Gonorrhea Therapeutics Market
